India

India develops first indigenous H5N1 bird flu vaccine

Pioneer News Service

Scientists at the ICAR-National Institute of High Security Animal Diseases (NIHSAD), Bhopal, have developed an indigenous vaccine to protect poultry from bird flu, described as the world’s first vaccine against the H5N1 clade 2.3.2.1a variant. Union Agriculture Minister Shivraj Singh Chouhan dedicated the vaccine to the nation on Friday and directed officials to expedite its commercial production.

The vaccine is expected to cost between Rs 1 and Rs 2 per dose. A booster dose will be required 21 days after the first dose, and its protective effect is expected to last for six months. According to scientists, the vaccine will be useful for egg-laying hens and breeding birds and could help reduce large-scale culling during bird flu outbreaks.

Chouhan also announced the construction of a BSL-4 laboratory at ICAR-NIHSAD in Bhopal at an estimated cost of `300 crore. He said scientists had to follow stringent safety protocols while developing the vaccine.

They were required to bathe with 120 litres of water after returning home from the laboratory and were prohibited from keeping pets during the research period.

The vaccine technology will be transferred for commercial production through Agrinnovate India. The vaccine will be available in the market after production arrangements and other necessary formalities are completed. Chouhan asked officials to speed up the process.

ICAR Director General ML Jat said no vaccine was previously available anywhere in the world against this particular H5N1 variant. He described the development as a significant achievement by Indian scientists.

Chouhan said animal husbandry was an important source of income for farmers, but livestock diseases caused annual losses of around Rs 56,000 crore.

These included losses of Rs 22,000 crore due to foot-and-mouth disease, Rs 20,000 crore due to lumpy skin disease, Rs 9,212 crore due to brucellosis and Rs 4,683 crore due to PPR. The vaccine research began at ICAR-NIHSAD in September 2025 under the guidance of Dr Aniket Sanyal and the leadership of Dr S Nagarajan. It was developed in August 2026 and subsequently underwent testing at the institute.

During trials, vaccinated chickens were exposed to the bird flu virus. Scientists reported that the virus did not spread to other chickens kept alongside them.

India has reported more than 500 cases of H5N1 and H5N8 bird flu since 2006. In infected poultry flocks, mortality can reach 100 per cent. Outbreaks often necessitate the culling of large numbers of birds, causing heavy losses to poultry farmers and affecting the environment. The new vaccine is expected to help contain such losses and reduce the risk of transmission to humans.